LIVN vs. PEN, GKOS, STVN, BLCO, INSP, NARI, PRCT, NVST, IRTC, and NVCR
Should you be buying LivaNova stock or one of its competitors? The main competitors of LivaNova include Penumbra (PEN), Glaukos (GKOS), Stevanato Group (STVN), Bausch + Lomb (BLCO), Inspire Medical Systems (INSP), Inari Medical (NARI), PROCEPT BioRobotics (PRCT), Envista (NVST), iRhythm Technologies (IRTC), and NovoCure (NVCR). These companies are all part of the "medical equipment" industry.
LivaNova vs.
Penumbra (NYSE:PEN) and LivaNova (NASDAQ:LIVN) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, valuation, risk, institutional ownership, profitability, community ranking, media sentiment and dividends.
Penumbra has a beta of 0.52, indicating that its stock price is 48% less volatile than the S&P 500. Comparatively, LivaNova has a beta of 1.01, indicating that its stock price is 1% more volatile than the S&P 500.
Penumbra has a net margin of 2.97% compared to LivaNova's net margin of 1.91%. LivaNova's return on equity of 13.81% beat Penumbra's return on equity.
In the previous week, Penumbra had 1 more articles in the media than LivaNova. MarketBeat recorded 4 mentions for Penumbra and 3 mentions for LivaNova. Penumbra's average media sentiment score of 0.50 beat LivaNova's score of 0.20 indicating that Penumbra is being referred to more favorably in the media.
Penumbra has higher revenue and earnings than LivaNova. LivaNova is trading at a lower price-to-earnings ratio than Penumbra, indicating that it is currently the more affordable of the two stocks.
Penumbra received 424 more outperform votes than LivaNova when rated by MarketBeat users. Likewise, 80.29% of users gave Penumbra an outperform vote while only 69.42% of users gave LivaNova an outperform vote.
88.9% of Penumbra shares are held by institutional investors. Comparatively, 97.6% of LivaNova shares are held by institutional investors. 5.0% of Penumbra shares are held by company insiders. Comparatively, 0.3% of LivaNova shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Penumbra presently has a consensus price target of $258.00, suggesting a potential downside of 2.30%. LivaNova has a consensus price target of $69.17, suggesting a potential upside of 43.20%. Given LivaNova's stronger consensus rating and higher possible upside, analysts clearly believe LivaNova is more favorable than Penumbra.
Summary
Penumbra beats LivaNova on 12 of the 18 factors compared between the two stocks.
Get LivaNova News Delivered to You Automatically
Sign up to receive the latest news and ratings for LIVN and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
LivaNova Competitors List
Related Companies and Tools
This page (NASDAQ:LIVN) was last updated on 1/20/2025 by MarketBeat.com Staff